Effect of oxymatrine HSPC liposomes on improving bioavailability, liver target distribution and hepatoprotective activity of oxymatrine

Cai, 1997, Clinical efficacy of kurorinone in the treatment of chronic hepatitis B, Acad. J. Sec. Mil. Med. Univ., 18, 47 Chai, 2012, OMT liposome attenuates hepatic fibrosis via targeting hepatic stellate cells, World J. Gastroenterol., 18, 4199, 10.3748/wjg.v18.i31.4199 Dai, 2015, Progress in mechanism of father-infant dissemination of hepatitis B virus, J. Jilin. Med. Coll, 36, 216 Dong, 2002, Effects of OMT on the serum levels of T helper cell 1 and 2 cytokines and the expression of the S gene in hepatitis B virus S gene transgenic mice: a study on the anti-hepatitis B virus mechanism of OMT, J. Gastroenterol. Hepatol., 17, 1299, 10.1046/j.1440-1746.2002.02885.x Du, 2006, Studies on the encapsulation of OMT into liposomes by ethanol injection and pH gradient method, Drug Dev. Ind. Pharm., 32, 791, 10.1080/03639040600760556 Gao, 2012, Hepatoprotective effect of MT salvianolic acid B salt on carbon tetrachloride-induced hepatic fibrosis, J. Inflamm., 9, 1051, 10.1186/1476-9255-9-16 Kneidl, 2014, Thermosensitive liposomal drug delivery systems: state of the art review, Int. J. Nanomedicine, 4387 Li, 2016, Increased cutaneous wound healing effect of biodegradable liposomes containing madecassoside: preparation optimization, in vitro dermal permeation, and in vivo bioevaluation, Int. J. Nanomedicine, 11, 2995, 10.2147/IJN.S105035 Liu, 1994, The effect of Chinese hepatoprotective medicines on experimental liver injury in mice, J. Ethnopharmacol., 42, 183, 10.1016/0378-8741(94)90084-1 Liu, 2002, Recommendations for prevention and treatment and studies of viral and chronic hepatitis, Natl. Med. J., 82, 74 Lu, 2003, OMT therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial, World J. Gastroenterol., 9, 2480, 10.3748/wjg.v9.i11.2480 Lu, 2004, Inhibitory effect of OMT on serum hepatitis B virus DNA in HBV transgenic mice, World J. Gastroenterol., 10, 1176, 10.3748/wjg.v10.i8.1176 Mao, 2004, Capsule OMT in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study, World J. Gastroenterol., 10, 3269, 10.3748/wjg.v10.i22.3269 Niven, 1990, Nebulization of liposomes. I. Effects of lipid composition, Pharm. Res., 7, 1127, 10.1023/A:1015924124180 Parvez, 2016, Antiviral natural products against chronic hepatitis B: recent developments, Curr. Pharm. Design., 22, 286, 10.2174/1381612822666151112152733 Pons, 1993, Liposomes obtained by the ethanol injection method, Int. J. Pharm., 95, 51, 10.1016/0378-5173(93)90389-W Ryu, 1995, The structure of kushenol M from Sophora flavescens, Arch. Pharm. Res., 18, 41, 10.1007/BF02976506 Scherphof, 2001, The role of hepatocytes in the clearance of liposomes from the blood circulation, Prog. Lipid Res., 40, 149, 10.1016/S0163-7827(00)00020-5 Wang, 1997 Wang, 2003, Pharmacokinetic study of OMT injection in Chinese healthy volunteers, J. Clin. Pharmacol., 19, 301 Wang, 2011, OMT inhibits hepatitis B infection with an advantage of overcoming drug-resistance, Antivir. Res., 89, 227, 10.1016/j.antiviral.2011.01.005 World Health Organization Yagi, 1989, Antifungal substances from Sophora flavescens, Shoyakugaku Zasshi, 43, 343 Yang, 2014, Targeted delivery of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic drug OMT on cultured hepatic stellate cells and liver fibrosis in rats, Eur. J. Pharmacol., 52, 180, 10.1016/j.ejps.2013.11.017 Zeng, 2015, Identification of MT as a promising novel drug for hepatic steatosis and glucose intolerance with HSP72 as an upstream target, Brit. J. Pharmacol., 172, 4303, 10.1111/bph.13209 Zhang, 2001, Antifibrotic effects of MT on in vitro and in vivo models of liver fibrosis in rats, Acta Pharmacol. Sin., 22, 183 Zhang, 2014, Liposomal OMT in hepatic fibrosis treatment: formulation, in vitro and in vivo assessment, AAPS PharmSciTech, 15, 620, 10.1208/s12249-014-0086-y